| Autor: |
Richard S. Judson, Doris Smith, Michael DeVito, John F. Wambaugh, Barbara A. Wetmore, Katie Paul Friedman, Grace Patlewicz, Russell S. Thomas, Risa R. Sayre, Jennifer H. Olker, Sigmund Degitz, Stephanie Padilla, Joshua A. Harrill, Timothy Shafer, Kelly E. Carstens |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Toxics, Vol 12, Iss 4, p 271 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2305-6304 |
| DOI: |
10.3390/toxics12040271 |
| Popis: |
Per- and polyfluoroalkyl substances (PFAS) are widely used, and their fluorinated state contributes to unique uses and stability but also long half-lives in the environment and humans. PFAS have been shown to be toxic, leading to immunosuppression, cancer, and other adverse health outcomes. Only a small fraction of the PFAS in commerce have been evaluated for toxicity using in vivo tests, which leads to a need to prioritize which compounds to examine further. Here, we demonstrate a prioritization approach that combines human biomonitoring data (blood concentrations) with bioactivity data (concentrations at which bioactivity is observed in vitro) for 31 PFAS. The in vitro data are taken from a battery of cell-based assays, mostly run on human cells. The result is a Bioactive Concentration to Blood Concentration Ratio (BCBCR), similar to a margin of exposure (MoE). Chemicals with low BCBCR values could then be prioritized for further risk assessment. Using this method, two of the PFAS, PFOA (Perfluorooctanoic Acid) and PFOS (Perfluorooctane Sulfonic Acid), have BCBCR values < 1 for some populations. An additional 9 PFAS have BCBCR values < 100 for some populations. This study shows a promising approach to screening level risk assessments of compounds such as PFAS that are long-lived in humans and other species. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
